Senior Scientist, Assay Development
Biofidelity’s mission is to improve and extend cancer patients’ lives by enabling better targeting of therapies, early detection of treatment resistance, and routine monitoring of treatment response. Our unique technology has been designed to allow rapid, broad adoption of our assays in testing labs around the world, enabling a step change in patient care.
Biofidelity has developed a revolutionary molecular diagnostic assay, enabling the rapid, ultra-sensitive detection of target DNA sequences with a transformational simplification of workflows.
Using just four steps and standard laboratory instrumentation, our assays can detect as little as a single molecule of mutated DNA against the background of billions of healthy molecules present in a typical patient sample, enabling straightforward detection of clinically actionable genetic markers at the earliest possible stage.
Biofidelity is expanding its clinical assay team responsible for the development of molecular diagnostic assays based on its core technology. We are seeking experienced, ambitious diagnostic development scientists to build and validate these assays as we take our technology into the clinic.
With a strong background in molecular diagnostics, you will have established experience in the development, optimisation and validation of clinical diagnostic assays. The ideal candidate would have experience in at least some of the following areas:
- Molecular diagnostic assay development & optimisation
- Laboratory automation
- Design & execution of diagnostic validation trials
- Biostatistics & data analysis
We offer the chance to join a rapidly growing team working on meaningful technologies with the potential for substantial real-world impact, coupled with an excellent working environment, a competitive salary, and a comprehensive benefits package including private medical cover, company share option scheme and 26 days per year holiday allowance.
To apply, please email your CV and cover letter to firstname.lastname@example.org.